Relaxation therapy studied for brain tumor anxiety – but trial cut short
NCT ID NCT05189366
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding sophrology (a relaxation method using breathing, visualization, and gentle movement) to speech therapy could reduce anxiety in people with aggressive brain tumors. Only 13 patients were enrolled before the trial was stopped early. The goal was to see if this combination improved anxiety levels and quality of life compared to speech therapy alone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- sophrology (relaxation therapy)
- What this could lead to
- If it had worked, this approach could have offered a simple, drug-free way to reduce anxiety and improve quality of life for brain tumor patients with speech difficulties.
- What could go wrong
- The trial was terminated early and enrolled only 13 people, so results are very limited. It is unclear if sophrology provides any real benefit over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
13 people
The number who actually took part.
- Started
-
Oct 2022
- Finished
-
Nov 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with histologically proven grade III and IV glial tumours requiring speech therapy; * Patient willing to start outpatient speech therapy; * Patient aged 18 years and over; * Informed patient who has signed consent; * Patient affiliated to a social security scheme. Exclusion Criteria: * Patient who has already had an initiation to sophrology in the context of his pathology; * Performance Status ≥ 4 ; * Patients suffering from psychiatric disorders; delusional phases, schizophrenia against the practice of sophrology; * Patient unable to follow the protocol (filling in questionnaires, attendance of sophrology and/or speech therapy sessions) for geographical, social or psychological reasons; * Patients who do not speak French; * Persons deprived of their liberty, under court protection, under curators or under the authority of a guardian. * Women who are pregnant, likely to be pregnant or breastfeeding;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Glial tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, 44805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.